Health Catalyst beats Q1 adjusted EBITDA expectations; net loss widens on impairment charge

Health Catalyst

11/05/2026 21:25

Overview

US healthcare intelligence firm's Q1 revenue fell 11% yr/yr

Q1 adjusted EBITDA rose 46% and beat analyst expectations

Company posted large net loss after $95.5 mln goodwill impairment

Outlook

Health Catalyst expects Q2 2026 revenue of $68 mln to $70 mln

Company sees Q2 2026 adjusted EBITDA of $9 mln to $10 mln

Health Catalyst expects 2026 revenue of $260 mln to $265 mln

Result Drivers

STRATEGIC RESET - Co said it began a strategic reset to focus on top technology opportunities, aiming to build a more durable business, per CEO Ben Albert

RESTRUCTURING COSTS - Co incurred restructuring costs related to workforce reductions and board changes during the qtr

Company press release: ID:nGNX44f2vG

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Net Income
-$111.03 mln
Q1 Adjusted EBITDA
Beat
$9.14 mln
$8.10 mln (9 Analysts)
Q1 Adj. Gross Margin
51.00%


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy", 7 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the software peer group is "buy."

Wall Street's median 12-month price target for Health Catalyst Inc is $2.00, about 31.6% above its May 8 closing price of $1.52

The stock recently traded at 11 times the next 12-month earnings vs. a P/E of 6 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)